Among the findings of the paper was the impact of the chemotherapy temozolomide (TMZ) on low-grade gliomas; in six patients, tumor samples acquired after treatment with TMZ showed hypermutation and progression to high-grade glioblastoma in the context of MGMT silencing and loss of mismatch repair. The gene discussed is MGMT; the disease is central nervous system cancer.